Precision BioSearch expands C-suite team of SENISCA with COO and CDO appointments
Precision BioSearch partnered with SENISCA, an award-winning biotechnology company developing RNA based therapeutics to reverse cellular senescence and target age-related disease
‘How to be an early-stage Biotech CEO in challenging times’, cited by Citeline
Our Co-founder, Malcolm Silander, chaired the discussion which formed the basis of Andrew McConaghie’s (In Vivo / Citeline) recent article, ‘How to be an early-stage Biotech CEO in challenging times’.
Precision BioSearch, corporate sponsorship of Bio Equity Europe 2023
Precision BioSearch is delighted to announce our corporate sponsorship of Bio Equity Europe 2023, being held from May 14-16th in Dublin, Ireland.
NRG Therapeutics partners with Precision BioSearch to expand management team
Precision BioSearch was pleased to partner with NRG Therapeutics, an innovative neuroscience company targeting mitochondrial dysfunction, to secure Gilles Ouvry as VP Chemistry and Vad Lazari as VP Biology.
Hiring with precision: how biotech investment headwinds impact leadership hiring
After several record years for biotech investment, the market has taken a downward turn in the past year.
Precision BioSearch secures CEO for Oxford spin-out, Dark Blue Therapeutics
Precision BioSearch partnered with Dark Blue Therapeutics, a biotech company developing a pipeline of oncology programs from the University of Oxford and therapeutics accelerator LAB282.
Tom Coulter joins Dalriada as Head, Drug Discovery Programs and Partnerships
Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.
New Oxford spin-out, Alethiomics, appoints Dr Edward Ainscow as CSO
Precision BioSearch is pleased to have partnered with Oxford Science Enterprises during the launch phase of Alethiomics to secure Dr Edward Ainscow as CSO